Strategic Product/Regulatory Development via Partner Ecosystem
OneSource Partner Secures Tentative U.S. ANDA Approval for Generic Ozempic; OneSource Supports as CDMO Partner
NSE
onesource
BSE
544292
OneSource announced that its partner Orbicular and its U.S.-based front-end partner have received tentative U.S. FDA ANDA approval for a generic version of Ozempic (Semaglutide Injection), with OneSource acting as CDMO partnersupporting end-to-end manufacturing for U.S. market filing and potential commercial supply.
PRICE-SENSITIVE TRIGGER
Event: Tentative U.S. FDA ANDA approval (partner-led)
Type: Strategic Product/Regulatory Development via Partner Ecosystem
Impact: Positive
Immediate Effect: Strengthens OneSource’s CDMO credentials in complex drug-device products and supports future commercial opportunity
Financial Snapshot
- Regulatory Milestone: Tentative ANDA Approval
- Product: Generic Ozempic (Semaglutide Injection)
- Role of OneSource: CDMO manufacturing partner
- Market: U.S.
Highlight:
Positive regulatory milestone linked to future commercial supply opportunity for OneSource as CDMO partner.
What Happened ?
OneSource disclosed that its partner Orbicular, along with its front-end partner, received tentative approval from the U.S. FDA for an ANDA referencing generic Ozempic.
OneSource supported the program as contract development and manufacturing organization (CDMO) partner, including manufacturing support tied to the U.S. filing.
key highlights
Regulatory Milestone
- Tentative approval granted
- Product tied to generic Semaglutide Injection
- U.S. regulatory milestone achieved
OneSource Role
- CDMO partner to the program
- Manufacturing support provider
- Potential future commercial supply support
Strategic Significance
- Strengthens complex injectable / drug-device positioning
- Supports CDMO credibility in regulated markets
- Potential future revenue opportunity if commercialization progresses
Risk Analysis
Key Risks
- Approval is tentative, not full commercial launch approval
- Commercialization timing uncertainty
- Partner execution dependency
- Competitive and regulatory risks in generic market
Worst Case Scenario
Tentative approval does not translate into meaningful commercial supply revenues
Risk Level: Medium
Company Commentary
- Reinforces strength in CDMO capabilities
- Supports expansion in complex drug-device opportunities
- Highlights strategic collaboration-led growth model
Official Exchange Filing: OneSource Speciality Pharma Limited